乳腺癌患者血浆D-二聚体水平的变化及其与临床病理的关系  

Plasma levels of D-dimer in patients with breast cancer and its relation to clinicopathologic features of disease

作　　者：吴杰[1] 徐笑红[1] 包叶江[1] 张剑英[1] 郑林峰[1] 陈道宝[1] 骆骥才[2] 

机构地区：[1]浙江省肿瘤医院,杭州310022 [2]浙江大学医学院附属第一医院

出　　处：《浙江医学》2013年第14期1336-1338,共3页Zhejiang Medical Journal

摘　　要：目的探讨乳腺癌患者血浆D-二聚体水平变化的意义及其与临床病理因素的关系。方法采用免疫比浊法测定120例乳腺癌患者组和100例健康对照组的血浆D-二聚体水平,比较两组间的差异,同时分析不同临床病理因素下D-二聚体水平的差异。结果乳腺癌组血浆D-二聚体水平显著高于健康对照组(P<0.05),且在不同TNM分期之间有显著差异;同时血浆D-二聚体水平在三阴(ER、PR、HER2均为阴性)乳腺癌患者中要显著高于非三阴患者,在1年生存率的分组比较中也有显著差异。结论乳腺癌患者血液处于高凝和纤溶亢进状态,血浆D-二聚体的水平反映了乳腺癌的恶性程度,与乳腺癌的分期、进展和生存期密切相关,因此D-二聚体水平在乳腺癌血清学诊断和临床应用研究中均有重要价值。Objective To investigate the plasma D-dimer levels in patients with breast cancer and its relation to clinico- pathologic features of disease. Methods Plasma D-dimer levels were measued in 120 breast cancer patients and 100 healthy women, the relation between the plasma D-dimer levels and clinicopathologic features of the disease was analyzed. Results The plasma D-dimer levels in breast cancer group was significantly higher than those in control group （P〈0.05）; D-dimer levels in patients with advanced cancer, triple-negative cancer（ER, PR, HER2） and non-survivors were significantly higher than those in early cancer, non-triple-negative cancer and survivors （P〈0.05）. Conclusion The results indicate that the hypercoagulability status is present in breast cancer patients and plasma D-dimer may be a useful maker for the tumor stage, progression and sur- vival in patients with breast cancer.

关 键 词：D-二聚体 乳腺癌 ER PR P53 HER2 高凝 

分 类 号：R737.9[医药卫生—肿瘤]